Integrin receptor-targeted, doxorubicin-loaded cerium oxide nanoparticles delivery to combat glioblastoma.

Nanomedicine (London, England) Pub Date : 2024-06-20 Epub Date: 2024-06-24 DOI:10.1080/17435889.2024.2350357

Gayathri Koula, Venu Yakati, Hari Krishnareddy Rachamalla, Keerti Bhamidipati, Muralidharan Kathirvel, Rajkumar Banerjee, Nagaprasad Puvvada

{"title":"Integrin receptor-targeted, doxorubicin-loaded cerium oxide nanoparticles delivery to combat glioblastoma.","authors":"Gayathri Koula, Venu Yakati, Hari Krishnareddy Rachamalla, Keerti Bhamidipati, Muralidharan Kathirvel, Rajkumar Banerjee, Nagaprasad Puvvada","doi":"10.1080/17435889.2024.2350357","DOIUrl":null,"url":null,"abstract":"Aim: To assess the chemo-immunomodulatory effects of doxorubicin-loaded cerium oxide nanoparticles coated with oleyl amine-linked cyclic RGDfK peptide (CeNP+Dox+RGD) to target both gliomas and its tumor microenvironment (TME) via integrin receptors. Materials & methods: CeNP+Dox+RGD nanoparticles are synthesized by the sequential addition of cerium III chloride heptahydrate, beta-cyclodextrin, oleic acid, and F127 micelle (CeNP). Doxorubicin was then loaded into CeNPs and coated with oleyl amine-linked cyclic RGDfK peptide to form stable CeNP+Dox+RGD nanoparticles. Results: CeNP+Dox+RGD nanoparticles crossed blood-brain barrier (BBB) effectively and demonstrated threefold enhanced survivability in glioma-bearing mice. The IHC profiling of glial tumor cross-sections showed increased CD80 expression (M1 TAMs) and decreased arginase-1 expression (M2 TAMs). Conclusion: CeNP+Dox+RGD can be an immunotherapeutic treatment option to combat glioblastoma.","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":" ","pages":"1389-1406"},"PeriodicalIF":0.0000,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11318704/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanomedicine (London, England)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17435889.2024.2350357","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/24 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: To assess the chemo-immunomodulatory effects of doxorubicin-loaded cerium oxide nanoparticles coated with oleyl amine-linked cyclic RGDfK peptide (CeNP+Dox+RGD) to target both gliomas and its tumor microenvironment (TME) via integrin receptors. Materials & methods: CeNP+Dox+RGD nanoparticles are synthesized by the sequential addition of cerium III chloride heptahydrate, beta-cyclodextrin, oleic acid, and F127 micelle (CeNP). Doxorubicin was then loaded into CeNPs and coated with oleyl amine-linked cyclic RGDfK peptide to form stable CeNP+Dox+RGD nanoparticles. Results: CeNP+Dox+RGD nanoparticles crossed blood-brain barrier (BBB) effectively and demonstrated threefold enhanced survivability in glioma-bearing mice. The IHC profiling of glial tumor cross-sections showed increased CD80 expression (M1 TAMs) and decreased arginase-1 expression (M2 TAMs). Conclusion: CeNP+Dox+RGD can be an immunotherapeutic treatment option to combat glioblastoma.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

以整合素受体为靶向、负载多柔比星的氧化铈纳米颗粒用于抗击胶质母细胞瘤。

目的：评估氧化铈纳米粒子包覆油胺环RGDfK肽（CeNP+Dox+RGD）通过整合素受体靶向胶质瘤及其肿瘤微环境（TME）的化学免疫调节作用。材料与方法CeNP+Dox+RGD纳米粒子由七水氯化铈III、β-环糊精、油酸和F127胶束（CeNP）依次加入合成。然后将多柔比星负载到 CeNPs 中，并包覆上油酸胺连接的环状 RGDfK 肽，形成稳定的 CeNP+Dox+RGD 纳米粒子。结果CeNP+Dox+RGD纳米颗粒能有效穿过血脑屏障（BBB），在胶质瘤小鼠中的存活率提高了三倍。胶质瘤横截面的 IHC 图谱显示，CD80 表达增加（M1 TAMs），精氨酸酶-1 表达减少（M2 TAMs）。结论CeNP+Dox+RGD可作为抗击胶质母细胞瘤的免疫治疗方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Nanomedicine (London, England)

自引率

0.00%

发文量

期刊最新文献

Ultrasmall solid lipid nanoparticles as a potential innovative delivery system for a drug combination against glioma. Advances in Alzheimer's disease control approaches via carbon nanotubes. CD133-targeted afatinib nanomicelles for enhanced lung cancer theranostics. Correction. The emergence of inhalable RNA therapeutics and challenges faced - where to from here?